Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Cressey

Showing results (91-100 of 160) with videos related to

Pageof 16
Sort By:
Journal of Clinical Pharmacology|December 17, 2025
Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic ExposureSteven Sun, Mina Nikanjam, Mark Mirochnick, et al.
AIDS (London, England)|May 6, 2025
Assessment of the steady-state drug-drug interactions between dolutegravir and ritonavir-boosted darunavir in adolescentsSeef Abdalla, Alexandra Compagnucci, Alasdair Bamford, et al.
Journal of Clinical Pharmacology|January 11, 2016
A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated With Current Efavirenz-Based RegimensNontiya Homkham, Tim R Cressey, Lily Ingsrisawang, et al.
Plos Medicine|September 12, 2022
Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort studyJean de Dieu Tapsoba, Jane Cover, Christopher Obong'o, et al.
Paediatric Drugs|October 22, 2024
Optimising Paediatric HIV Treatment: Recent Developments and Future DirectionsAnne E M Kamphuis, Alasdair Bamford, Alfredo Tagarro, et al.
The Journal of Antimicrobial Chemotherapy|February 5, 2019
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modellingStein Schalkwijk, Rob Ter Heine, Angela Colbers, et al.
The Pediatric Infectious Disease Journal|May 11, 2010
A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in ThailandNirun Vanprapar, Tim R Cressey, Kulkanya Chokephaibulkit, et al.
Journal of the Pediatric Infectious Diseases Society|October 5, 2023
Abacavir Drug Exposures in African Children Under 14 kg Using Pediatric Solid Fixed Dose Combinations According to World Health Organization Weight BandsSuthunya Chupradit, Dalton C Wamalwa, Elizabeth Maleche-Obimbo, et al.
Clinical Pharmacology and Therapeutics|January 22, 2024
Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in AfricaSuthunya Chupradit, Dalton C Wamalwa, Elizabeth Maleche-Obimbo, et al.
The Pediatric Infectious Disease Journal|January 8, 2024
Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of AgeAdrie Bekker, Jincheng Yang, Jiajia Wang, et al.
Pageof 16

Showing results (91-100 of 160) with videos related to

Sort By:
Pageof 16
Journal of Clinical Pharmacology|December 17, 2025
Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic ExposureSteven Sun, Mina Nikanjam, Mark Mirochnick, et al.
AIDS (London, England)|May 6, 2025
Assessment of the steady-state drug-drug interactions between dolutegravir and ritonavir-boosted darunavir in adolescentsSeef Abdalla, Alexandra Compagnucci, Alasdair Bamford, et al.
Journal of Clinical Pharmacology|January 11, 2016
A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated With Current Efavirenz-Based RegimensNontiya Homkham, Tim R Cressey, Lily Ingsrisawang, et al.
Plos Medicine|September 12, 2022
Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort studyJean de Dieu Tapsoba, Jane Cover, Christopher Obong'o, et al.
Paediatric Drugs|October 22, 2024
Optimising Paediatric HIV Treatment: Recent Developments and Future DirectionsAnne E M Kamphuis, Alasdair Bamford, Alfredo Tagarro, et al.
The Journal of Antimicrobial Chemotherapy|February 5, 2019
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modellingStein Schalkwijk, Rob Ter Heine, Angela Colbers, et al.
The Pediatric Infectious Disease Journal|May 11, 2010
A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in ThailandNirun Vanprapar, Tim R Cressey, Kulkanya Chokephaibulkit, et al.
Journal of the Pediatric Infectious Diseases Society|October 5, 2023
Abacavir Drug Exposures in African Children Under 14 kg Using Pediatric Solid Fixed Dose Combinations According to World Health Organization Weight BandsSuthunya Chupradit, Dalton C Wamalwa, Elizabeth Maleche-Obimbo, et al.
Clinical Pharmacology and Therapeutics|January 22, 2024
Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in AfricaSuthunya Chupradit, Dalton C Wamalwa, Elizabeth Maleche-Obimbo, et al.
The Pediatric Infectious Disease Journal|January 8, 2024
Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of AgeAdrie Bekker, Jincheng Yang, Jiajia Wang, et al.
Pageof 16